You will be presented with a collection of medical randomized controlled trial (RCT) reports addressing a shared clinical question -- for instance, the efficacy of a medical intervention on a disease or condition. Given the titles and abstracts of these reports, your task is to generate the conclusion of the systematic review article synthesizing the key findings. Your conclusion should be a few sentences long. In your response, include only the conclusion and no other text. The RCT reports are below.



Title 1:
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
Abstract 1:
PURPOSE A multicenter phase II study to determine the activity and toxicity of Caelyx ( Doxil ; Sequus Pharmaceuticals Inc , Menlo Park , CA ) in patients with metastatic breast cancer . PATIENTS AND METHODS Seventy-one patients with stage IV breast cancer were treated with Caelyx at doses of 45 to 60 mg/m2 every 3 to 4 weeks for a maximum of six cycles . Twenty-eight patients had received prior chemotherapy with a nonanthracycline regimen . Fifty-two patients had disease at multiple sites . Hepatic and pulmonary disease were the predominant metastatic site in 50 patients . Response was assessable in 64 cases . RESULTS Sixteen patients achieved a partial response and a complete response ( overall response rate , 31 % ; ( 95 % confidence interval , 20 % to 43 % ) . Twenty patients ( 31 % ) had stable disease on treatment . Neutropenia > or = grade 3 occurred in 10 % of cycles ( 27 % of patients ) and mucositis > or = grade 3 in 10 % of cycles ( 32 % of patients ) . Significant alopecia was rare and routine prophylactic antiemetics were not required . At doses of 60 mg/m2 every 3 weeks , seven of 13 patients had > or = grade 3 skin toxicity ; overall , this toxicity complicated 25 % of treatment cycles . The incidence of > or = grade 3 skin toxicity was greatly reduced at doses of 45 mg/m2 every 4 weeks , occurring in five of 32 patients and affecting only 5 % of 126 treatment cycles . CONCLUSION Caelyx is an active agent in advanced breast cancer with a safety profile that differs markedly from nonliposomal doxorubicin . A regimen of 45 mg/m2 every 4 weeks was well tolerated in this cohort of women with advanced poor-prognosis breast cancer . The mild myelosuppression seen with this regimen would favor its use in combination chemotherapy
We found that the most important side effects of PLD were skin toxicity and mucositis , but the proportion of patients who showed grade III and IV of these side effects was relatively low .
On the other h and , the occurrence of cardiotoxicity , the most important problem with doxorubicin , was considerably reduced in patients treated with PLD .
Although PLD has demonstrated a lower toxicity profile than conventional anthracyclines , it has also new side effects .
However , it seems that the reduced cardiotoxicity of PLD has made it a more appropriate option in patients with MBC , especially in those with risk factors for cardiac diseases